Seattle Genetics has been offering solutions to problems like cancer through innovative development of antibody-based therapies. Seattle Genetics is a leading biotechnology company that has directed focus on developing ADCs ideal for the treatment of cancer. The antibody-drug conjugates (ADC) technology is a new addition that the company has embraced in a bid to offer broader solutions to complex conditions. ADCs help to reduce toxicity and do not interfere with non-targeted cells. Seattle Genetics is also creating a new product pipeline that will work on significant medical needs that are not met.
Invitations for clinical trials
Seattle Genetics also conducts clinical trials, which involve testing individuals during a research session mean to avail answers to new ways of preventing and treating diseases. The process also helps to offer information about methods that are best for diagnosing certain illnesses. Those who join the clinical trials contribute to the enhancement of scientific knowledge about cancer and help experts to come up with viable treatment options for cancer.
During the whole process, safety is taken care of. All the items that are used in the research are checked for functionality to ensure no volunteers are harmed in the process. Note that no drugs are administered directly because the process demands that individuals should only offer samples for research purposes.
Seattle Genetics also recognizes the effort of their employees, and this has inspired them to come up with the benefits package, which includes compensation, health and wellness, savings opportunities, work-life balance and career development packages. The company offers paid vacations and sick time to employees to relieve them of the hard tasks before they can resume work. This has worked by enhancing productivity among the employees, thereby ensuring all the products produced are high-quality.
Clay B. Siegall, Ph.D. co-founded the company in 1998 and has held a leadership position as the CEO for years. Mr. Siegall is a graduate of Genetics from the George Washington University. He also holds a degree in Zoology from Maryland University. Siegall is a proactive leader who has always been in the forefront financing and supporting research that can come up with new ways of treating cancer.